CytoDyn Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Webcast to provide company update on march 5, 2024 vancouver, washington, feb. 29, 2024 (globe newswire) -- cytodyn inc. (otcqb: cydy) ("cytodyn" or the "company"), a biotechnology company developing leronlimab, a ccr5 antagonist with the potential for multiple therapeutic indications, announced today that the fda has lifted the clinical hold on leronlimab. the company is now free to proceed with its proposed hiv clinical trial exploring leronlimab and its effects on chronic inflammation.

Vancouver, washington, feb. 01, 2024 (globe newswire) -- cytodyn inc. (otcqb: cydy) ("cytodyn" or the "company"), a biotechnology company developing leronlimab, a ccr5 antagonist with the potential for multiple therapeutic indications, announced today that the company has submitted its revised hiv clinical trial protocol to the fda. the company believes this submission will lead to the removal of the clinical hold currently in effect.

Vancouver, washington, jan. 29, 2024 (globe newswire) -- cytodyn inc. (otcqb: cydy) ("cytodyn" or the "company"), a biotechnology company developing leronlimab, a ccr5 antagonist with the potential for multiple therapeutic indications, announced today that dr. jacob lalezari, formerly interim ceo, was appointed to the ceo role, effective january 26, 2024.

New york , jan. 18, 2024 /prnewswire/ -- purcell & lefkowitz llp announces that it is investigating cytodyn inc. (otc: cydy) on behalf of the company's shareholders.  the investigation seeks to determine whether cytodyn's directors breached their fiduciary duties in connection with recent corporate actions.

Vancouver, washington, dec. 07, 2023 (globe newswire) -- cytodyn inc. (otcqb: cydy) ("cytodyn" or the "company"), a biotechnology company developing leronlimab, a ccr5 antagonist with the potential for multiple therapeutic indications, announced today that dr. jacob p. lalezari, interim chief executive officer, will host an investment community webcast to provide a company update on thursday, december 14, 2023. the company update will include discussion about recent comments from the fda concerning the clinical hold, an anticipated timeline to respond to the fda and resolve the clinical hold, the company's next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.

VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will host an investment community webcast to provide a Company update on Thursday, December 14, 2023. The Company update will include discussion about recent comments from the FDA concerning the clinical hold, an anticipated timeline to respond to the FDA and resolve the clinical hold, the Company's next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.

Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24 th , 2023, at 1 PM PT / 4 PM ET VANCOUVER, Washington, July 11, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed a supplemental Statement of Claim and formally requested a hearing date in its litigation proceeding against Amarex Clinical Research LLC (“Amarex”), the Company's former Contract Research Organization (“CRO”)...

VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023.

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.

The U.

Today, I'll discuss why new leadership brings new opportunities. I'll explain the concept of Net Present Value (NPV) and why it's utilized as a 'strategic assessment tool' to identify high value growth opportunities.

VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Kelly, Chief Medical Officer and Head of Business Development, will host an investment community webcast to provide a quarterly Company update on Wednesday, September 28, 2022.

TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs.

VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Director of Research & Development, will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022.

CytoDyn seems to be dead in the waters. In my view, it is tough to assess leronlimab scientifically because the data they have generated is suspect.